Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | NPC1 | O15118 | 8/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761263 | 0.93 | RAB9A (0.81) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| Oxalic Acid SCHEMBL7760042 | 0.90 | RAB9A (0.76) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| Oxalic Acid SCHEMBL7760911 | 0.86 | RAB9A (0.69) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7760900 | 0.86 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| Oxalic Acid SCHEMBL7762758 | 0.84 | RAB9A (0.66) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7963191 | 0.81 | RAB9A (0.81) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10220600 | 0.79 | RAB9A (0.72) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7756335 | 0.78 | RAB9A (0.74) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24986857 | 0.77 | RAB9A (0.67) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30164059 | 0.77 | RAB9A (0.67) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6291463-B1 | TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-09-18 | — | — | US | claimed |
| EP-1089990-A1 | 1-(BENZOTHIAZOL-2-YL)-4-(1-PHENYLMETHYL)PIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000000482-A1 | 1-(BENZOTHIAZOL-2-YL)-4-(1-PHENYLMETHYL)PIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-06 | — | — | WO | claimed |
| US-6291463-B1 | TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-09-18 | — | — | US | disclosed |
| EP-1089990-A1 | 1-(BENZOTHIAZOL-2-YL)-4-(1-PHENYLMETHYL)PIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000482-A1 | 1-(BENZOTHIAZOL-2-YL)-4-(1-PHENYLMETHYL)PIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-06 | — | — | WO | disclosed |